Project 03: Leukemia Research (LR)

项目总结-白血病研究（LR） 俄亥俄州州立大学综合癌症中心（OSUCCC）的白血病研究（LR）项目， 由John C.医学博士伯德和医学博士拉米罗加尔宗有来自7个系和4个学院的57名成员 （工程，药学，医学和兽医）。LR计划仍然专注于病因学， 白血病的发病机制、预后和治疗，重点是急性髓性白血病（AML）、慢性粒细胞白血病（CML）、 淋巴细胞白血病（CLL）、毛细胞白血病（HCL）和成人T细胞白血病（ATL）。LR证明 将临床前发现转化为临床试验并最终转化为临床应用的能力 应用程序.鉴于基础，临床前，转化和临床的广度，在LR计划中，我们将专注于 主要有以下两个目标：1）探索和整合遗传、表观遗传和非编码RNA， 白血病细胞的免疫抑制特征，以增强风险分层和靶点识别; 2） 促进表观遗传、靶向和免疫治疗的临床前和临床开发， 白血病转化的原因，其进展和最终重点是治愈这些疾病。LR计划 成员们在2014年12月1日至2019年11月30日期间发表了702篇与癌症相关的手稿。其中，33%是内部- 程序性的（多个作者来自LR程序），23%是跨程序的（多个作者来自LR程序） OSUCCC项目），77%是多机构（作者来自LR和另一家机构）。总 合作出版占88%。LR计划的资金总额为1170万美元，直接用于癌症 资金，其中630万美元是同行评审的，包括来自NIH的510万美元直接资金（来自NCI的490万美元）。来 在过去5年中，LR计划成员已累计8,835名参与者参加试验; 1,582名参与干预性试验 （包括1,556项治疗性试验）和7,253项非干预性试验。未来的计划包括：1）增强 合作科学，以进一步提高我们的发现和转化工作的质量; 2）进一步解剖 白血病的遗传亚型可能重新定义AML和CLL的分类和治疗方法， 精确的基于医学的方法; 3）整合患者友好的靶向和免疫治疗， 开发治愈性治疗方法;以及4）集中招募中级资助研究人员， 专门的研究领域，补充LR计划和Pelotonia免疫研究所， 肿瘤科总的来说，我们的计划致力于支持开发一种无化疗方法， 治疗白血病因此，这种策略将优先于传统的化疗方法， 早期研究者与BEAT AML和Alliance联盟一起沿着启动了试验。通过类似的路径， 将启动MDS试验（Stop MDS™），重点关注未满足需求的领域。最后，我们的节目将 支持提交计划赠款，如SPORE和P01，这将使我们能够实现我们的目标。 战略研究目标。这将通过提供试点资金和协调共享资源来实现， 这将有助于这些应用程序。

PROJECT SUMMARY – LEUKEMIA RESEARCH (LR) The Leukemia Research (LR) Program at The Ohio State University Comprehensive Cancer Center (OSUCCC), led by John C. Byrd, MD, and Ramiro Garzon, MD, has 57 members from 7 Departments and 4 Colleges (Engineering, Pharmacy, Medicine, and Veterinary Medicine). The LR Program remains focused on the etiology, pathogenesis, prognosis, and treatment of leukemia, with emphases on acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), hairy cell leukemia (HCL) and adult T-cell leukemia (ATL). LR has demonstrated unique strengths in its ability to translate preclinical findings to clinical testing, and ultimately to clinical application. Given the breadth of basic, preclinical, translational and clinical, within the LR Program, we will focus on the following two specific aims: 1) To Explore and integrate genetic, epigenetic, non-coding RNAs, and immunosuppressive features of leukemic cells in order to enhance risk stratification and target identification; 2) To foster preclinical and clinical development of epigenetic, targeted, and immunologic therapeutics directed at the causes of leukemic transformation, its progression and ultimate focus on curing these diseases. LR Program members published 702 cancer-relevant manuscripts between 12/01/14 and 11/30/19. Of these, 33% were intra- programmatic (multiple authors from LR Program), 23% were inter-programmatic (authors from multiple OSUCCC Programs), and 77% were multi-institutional (authors from both LR and another institution). The total collaborative publications is 88%. LR Program funding stands at $11.7M in overall direct, cancer-focused funding, of which $6.3M is peer-reviewed, including $5.1M direct funding from NIH ($4.9M from NCI). Over the last 5 years, LR Program members have accrued 8,835 participants to trials; 1,582 to interventional trials (including 1,556 therapeutic trials) and 7,253 to non-interventional trials. Future plans include: 1) enhancement of collaborative science to further improve the quality of our discovery and translational work; 2) further dissection of the genetic subtypes of leukemia to potentially re-define how AML and CLL are classified and treated using precision medicine-based approaches; 3) integration of patient-friendly, targeted and immune therapies to develop curative treatment approaches; and 4) focused recruiting of mid-level funded investigators with dedicated research areas that complement the LR Program and also the Pelotonia Institute for Immuno- Oncology. Overall, our program is committed to support the development of a chemotherapy-free approach to treat leukemia. Therefore, this strategy will be prioritized over conventional chemotherapy approaches through early investigator initiated trials along with the BEAT AML and the Alliance consortia. Through a similar path, an MDS trial (Stop MDS™) will be been initiated and will focus on an area of unmet need. Last, our program will support the submission of programmatic grants such as SPORE and P01 that will allow us to achieve our strategic research goals. This will be achieved by providing pilot funding and coordinating shared resources that will facilitate such applications.